-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] As of the close of March 7, there were 12 stocks in the pharmaceutical and biological sector, including Dali Pharmaceutical, Dajia Weikang, China Pharmaceutical, First Pharmaceutical, Gongtong Pharmaceutical, Haichen Pharmaceutical, etc.
The industry mainly focuses on traditional Chinese medicine, pharmaceutical business, chemical raw materials, medical services and other sub-sectors
.
As of the close on March 7, Gongtong Pharmaceutical closed at 60.
82 yuan, a change of 20.
01%, a turnover rate of 58.
79%, and a turnover of 963 million yuan
.
The company announced on the evening of March 7 that the stock trading of Hubei Gongtong Pharmaceutical Co.
, Ltd.
had a cumulative deviation of more than 30% of the daily closing price increase within two consecutive trading days (March 4, 2022, March 7, 2022)
.
After verification, the company, the controlling shareholder and the actual controller do not have any major events that should be disclosed but have not been disclosed, nor do they have major events in the planning stage
.
According to the data, Gongtong Pharmaceutical is a company specializing in the research and development, production and sales of steroid drug raw materials.
The main products are the starting materials and intermediates required for the production of steroid drugs
.
Dali Pharmaceutical Dali Pharmaceutical closed at 11.
09 yuan on March 7, an increase of 10.
02%, a turnover rate of 11.
66%, and a turnover of 275 million
.
The company issued an announcement in the evening that the company's stock on March 4, 2022, and March 7, 2022, the closing price of the company's stock has increased by more than 20% for two consecutive trading days, which is an abnormal fluctuation in stock trading
.
The company's stock price will increase by the limit for 4 consecutive trading days on March 2, 2022, March 3, 2022, March 4, 2022, and March 7, 2022, and the deviation of the closing price increase for 4 consecutive trading days is accumulatively 43.
42%
.
After the company's self-inspection and written consultation with the controlling shareholder and actual controller, as of the disclosure date of this announcement, there is no material information that should be disclosed but has not been disclosed
.
According to the data, Dali Pharmaceutical's main business includes the production and sales of Chinese and Western medicine injections
.
Dajia Weikang As the concept of assisted reproduction continues to strengthen, Dajia Weikang also opened the daily limit on March 7, and the daily closed at 36.
44 yuan, an increase of 19.
99%, a turnover rate of 12.
29%, and a turnover of 219 million
.
On the news, Dajia Weikang stated on the investor interaction platform on March 7 that the company is mainly engaged in the distribution and retail business of medicines, biological products, medical devices and other products.
Store layout, as of September 30, 2021, the number of professional pharmacies in the company has tripled; as a regional distribution company, the company operates tens of thousands of pharmaceutical products, and is one of the main distributors of upstream pharmaceutical companies in Hunan Province.
A certain product has little impact on the company's revenue ratio.
Investors are advised to make decisions carefully and pay attention to preventing investment risks
.
Affected by the rumors that Sinopharm and Pfizer have reached a cooperation on Paxlovid, Sinopharm has won the fourth consecutive board from March 2 to March 7
.
As of the close on March 7, China Pharmaceutical closed at 16.
25 yuan, an increase of 10.
02%, a turnover rate of 1.
05%, and a turnover of 183 million
.
On March 4, Sinopharm issued an announcement on abnormal fluctuations in stock trading, saying that after verification, the above-mentioned rumors are currently being communicated and negotiated, but there are still uncertainties about the specific terms of the agreement and whether it can be successfully signed
.
On March 7, the relevant person in charge of Pfizer told the media that the commercialization of the Paxlovid drug has not yet been confirmed, whether it is the cooperation with China Pharmaceuticals or the hospital's emergency department
.
First Medicine The trading public information released by the Shanghai and Shenzhen Stock Exchanges on March 07, 2022 shows that First Medicine was listed on the list because it became a security with a deviation of 7% on the day and a cumulative 20% deviation of the closing price within three consecutive trading days.
.
As of the close on March 7, First Medicine closed at 12.
71 yuan, an increase of 10.
04%, a turnover rate of 11.
45%, and a turnover of 310 million
.
According to the data, First Medicine is mainly engaged in the retail and wholesale business of pharmaceuticals
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The industry mainly focuses on traditional Chinese medicine, pharmaceutical business, chemical raw materials, medical services and other sub-sectors
.
As of the close on March 7, Gongtong Pharmaceutical closed at 60.
82 yuan, a change of 20.
01%, a turnover rate of 58.
79%, and a turnover of 963 million yuan
.
The company announced on the evening of March 7 that the stock trading of Hubei Gongtong Pharmaceutical Co.
, Ltd.
had a cumulative deviation of more than 30% of the daily closing price increase within two consecutive trading days (March 4, 2022, March 7, 2022)
.
After verification, the company, the controlling shareholder and the actual controller do not have any major events that should be disclosed but have not been disclosed, nor do they have major events in the planning stage
.
According to the data, Gongtong Pharmaceutical is a company specializing in the research and development, production and sales of steroid drug raw materials.
The main products are the starting materials and intermediates required for the production of steroid drugs
.
Dali Pharmaceutical Dali Pharmaceutical closed at 11.
09 yuan on March 7, an increase of 10.
02%, a turnover rate of 11.
66%, and a turnover of 275 million
.
The company issued an announcement in the evening that the company's stock on March 4, 2022, and March 7, 2022, the closing price of the company's stock has increased by more than 20% for two consecutive trading days, which is an abnormal fluctuation in stock trading
.
The company's stock price will increase by the limit for 4 consecutive trading days on March 2, 2022, March 3, 2022, March 4, 2022, and March 7, 2022, and the deviation of the closing price increase for 4 consecutive trading days is accumulatively 43.
42%
.
After the company's self-inspection and written consultation with the controlling shareholder and actual controller, as of the disclosure date of this announcement, there is no material information that should be disclosed but has not been disclosed
.
According to the data, Dali Pharmaceutical's main business includes the production and sales of Chinese and Western medicine injections
.
Dajia Weikang As the concept of assisted reproduction continues to strengthen, Dajia Weikang also opened the daily limit on March 7, and the daily closed at 36.
44 yuan, an increase of 19.
99%, a turnover rate of 12.
29%, and a turnover of 219 million
.
On the news, Dajia Weikang stated on the investor interaction platform on March 7 that the company is mainly engaged in the distribution and retail business of medicines, biological products, medical devices and other products.
Store layout, as of September 30, 2021, the number of professional pharmacies in the company has tripled; as a regional distribution company, the company operates tens of thousands of pharmaceutical products, and is one of the main distributors of upstream pharmaceutical companies in Hunan Province.
A certain product has little impact on the company's revenue ratio.
Investors are advised to make decisions carefully and pay attention to preventing investment risks
.
Affected by the rumors that Sinopharm and Pfizer have reached a cooperation on Paxlovid, Sinopharm has won the fourth consecutive board from March 2 to March 7
.
As of the close on March 7, China Pharmaceutical closed at 16.
25 yuan, an increase of 10.
02%, a turnover rate of 1.
05%, and a turnover of 183 million
.
On March 4, Sinopharm issued an announcement on abnormal fluctuations in stock trading, saying that after verification, the above-mentioned rumors are currently being communicated and negotiated, but there are still uncertainties about the specific terms of the agreement and whether it can be successfully signed
.
On March 7, the relevant person in charge of Pfizer told the media that the commercialization of the Paxlovid drug has not yet been confirmed, whether it is the cooperation with China Pharmaceuticals or the hospital's emergency department
.
First Medicine The trading public information released by the Shanghai and Shenzhen Stock Exchanges on March 07, 2022 shows that First Medicine was listed on the list because it became a security with a deviation of 7% on the day and a cumulative 20% deviation of the closing price within three consecutive trading days.
.
As of the close on March 7, First Medicine closed at 12.
71 yuan, an increase of 10.
04%, a turnover rate of 11.
45%, and a turnover of 310 million
.
According to the data, First Medicine is mainly engaged in the retail and wholesale business of pharmaceuticals
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
